1 / 96

Multiple Sclerosis

Multiple Sclerosis. Diagnosis, Treatment, Disability J. Scott Pritchard, DO NADE National Training Conference - 2011. History. Other clinical names- -encephalomyelitis disseminata -disseminated sclerosis

mona-stein
Download Presentation

Multiple Sclerosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Multiple Sclerosis Diagnosis, Treatment, Disability J. Scott Pritchard, DO NADE National Training Conference - 2011

  2. History • Other clinical names- -encephalomyelitis disseminata -disseminated sclerosis • First described by Jean-Martin Charcot in 1868 – Charcot’s triad • Anecdotal histories suggest the disease has been recognized since 1200 - Halldora • First well documented case – Sir Frederick D' Este’s personal diary 1822 - 1846

  3. Inflammatory auto-immune disease affecting the fatty myelin sheaths of the brain/spinal cord axons Demyelination and remyelination Scarring – Sclerosis (plaques/lesions) Loss of conduction – electrical signal Genetic, environmental and infectious etiologies have been suggested Progressive and incurable

  4. Great Mimic • The initial symptoms are varied, vague and extremely difficult to link to a specific cause • Numbness, tingling, muscle weakness, changes in cognition, nystagmus, optic neuritis, diplopia, difficulty swallowing or speaking, unexplained fatigue or depression • Symptoms often increased with stress or increased heat (Uhthoff’s phenomenon) exercise or environmental

  5. Physical examination • Often very non-focal. Mild motor weakness. Non-dermatomal sensory loss • Lhermitte’s phenomenon • Optic Neuritis • INO-intranuclear ophthalmoplegia • Myelopathy-seen with transverse myelitis • Motor weakness. Fatigability of muscles with activity. Generalized fatigue • Spasticity – Ashworth scale – zero to four (severe) • Ataxia • MMSE

  6. Clinical testing • SSEP/VEP - evoked potentials • +CSF for increased IgG synthesis and oligoclonal bands • MRI-brain/spinal cord w/gadolinium • McDonald ‘s criteria-clinical, laboratory and radiographic evidence • NPS • Myelin Basic Protein- CSF • NMO antibodies

  7. Classification of MS • Relapsing-remitting-periods of clinical worsening that resolves with time. However, baseline function is not restored • Secondary progressive (galloping MS) • Primary progressive-later onset w/minimal recovery • Progressive relapsing-progressive decline with superimposed attacks (Devic’s dz)

  8. Treatment • The goal of all therapies is slow disease progression. • Inflammation – Solu-Medrol • Immunomodulation – Avonex/Rebif, Betaseron, Copaxone (ABC therapies) • Antineoplastics – Mitoxantrone • Monoclonal AB - Natalizumab (Tysabri)

  9. New Treatments • Extavia- Interferon -generic • Cladribine- antineoplastic • Rituximab- biologic agent-antineoplastic • Myelin Basic Protein Supplement • Oral therapies recently released 1. Ampyra – Improves gait in RR MS 2. BG – 12 - RRMS 3. Gilenya – decreases freq/severity

  10. Disability • 25 foot walk test- normal- 5 seconds- men - 6 seconds- women • EDSS-Expanded Disability Status Scale Steps from 0-10-Inviduals 1.0-4.5 are fully ambulatory. 5.0-9.5-increasing ambulatory impairment. 10-Death A claimant with an EDSS of 5.0 or > would typically be disabled.

  11. Listings 11.09 A - Reference listing to 11.04 B 11.09 B - Reference to listings 2.02,2.03,2.04 and 12.02 11.09 C –Reproducible, substantial motor weakness w/repetitive use or movement

  12. SSR 96 – 8p • DI 24510.057 • Sustainability of an RFC – consider the functional impact of fatigue and pain • Is the claimant able to sustain a 40 HR work week?

  13. Case Studies • 57 y/o clt. 1970- numbness of the face and double vision. 1982-RLE numbness that spread to the LLE not relieved by surgery.1983 OS visual loss w/Lhermitte’s phenomenon. Subsequent years intermittent numbness, diplopia. 1993 major exacerbation with difficulty walking. These episodes progressed to present. She reports mild impairment to mobility and ADL’s. Profound fatigue.

  14. #2 • 62 y/o clt. Onset of symptoms 1997. On Copaxone from 1998-2002. Four courses of Mitoxantrone. 2002-2003. Progressive weakness and fatigue. Last major relapse 2005. MRI’s document increasing plaque burden in the thoracic cord. • 25 foot walk-11 seconds with a walker • Progressive weakness in the afternoon

  15. #3 • 54 y/o clt – onset of R optic neuritis followed by L hemiparesis • Deep demyelinating lesion R hemisphere and cervical spine at C3 • Weakness occurs after walking 10-15 minutes • Spasticity of the LUE/LLE and 3/5 motor • Wide based gait and decreased RAM LUE

  16. #4 • 38 y/o clt – initial bout of optic neuritis at age 26. No other symptoms/clinical findings until the acute onset of mid-thoracic and abdominal pain. MRI documents a T12 lesion in the spinal cord A complete work-up rules out all other etiologies for her pain. Dx neuropathic pain secondary transverse myelitis at T12 All modalities to relieve pain were ineffective.

  17. Thank YOU !!!!

  18. Acknowledgements • Movies from the Neurologic Exam and PediNeurologic Exam were used with the permission of Paul d. Larsen, MD., University of Nebraska Medical Center and Suzanne S. Stensass, PhD. University of Utah School of Medicine. Additional materials were drawn from resources provided by Alejandro Stern, Stern Foundation, Buenos Aires, Argentina, Kathleen Digre, MD., University of Utah

  19. and Daniel Jacobson, MD., Marshfield Clinic, Wisconsin. The movies are licensed under a Creative Commons Attribution-Non-commercial ShareAlike 2.5 license

More Related